Business Wire

PA-PMI

Share
Project Management Institute Names Pierre Le Manh as New President & Chief Executive Officer

Project Management Institute (PMI) today announced that its Board of Directors has named Pierre Le Manh as President and Chief Executive Officer (CEO).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005706/en/

Starting September 1, Pierre Le Manh, a veteran CEO of professional services and knowledge industries, will lead PMI’s fast-growing global organization and oversee the continued execution of PMI’s Impact Strategy. In his role, Pierre will also serve as the lead advocate for PMI’s global organization and close to a hundred million project professionals worldwide.

“We are very excited to bring Pierre Le Manh on board after a thorough selection process,” said Jennifer Tharp, PMP, Chair of PMI’s Board of Directors. “We have big ambitions for the future of our profession and the Project Management Institute as a leading global organization. Pierre brings the global experience and credentials to accelerate PMI’s current business and further our innovation and transformation journey. As Michael DePrisco will resume his responsibilities as PMI’s chief operating officer, the Board and myself want to express our gratitude to Michael for serving as interim CEO during the selection process.”

Pierre Le Manh has served in CEO roles for over 20 years at knowledge, research, and technology-based companies worldwide. He has lived and worked in Paris, Montreal, London, Rome, and New York City. He brings a proven track record of growth, transformation, and globalization and a passion for team building and nurturing culture.

“Think about what project professionals have achieved across all sectors of the economy and society: from construction to technology, from healthcare to government, from consumer goods to infrastructure, from arts to sciences,” said Le Manh. “Maybe even more importantly, think of the daunting tasks ahead of them when humanity has no other choice than to pursue more sustainable development in the future. Without competent professionals to lead and run projects, ideas cannot be made a reality. Project professionals are the doers and builders of transformation.”

“I am eager to work with PMI’s Board, Michael DePrisco and the leadership team, and our growing global team of more than 700 permanent employees to take on the challenges of a new era, innovate and build upon PMI’s status as a fast-growing global leader in professional development, education, and upskilling,” continued Le Manh. “I enthusiastically look forward to meeting and working with the greater global mission-driven community of changemakers of more than 300 chapters, 10,000 volunteers, and close to 700,000 active PMI members to create better outcomes for individuals, businesses, and society worldwide.”

Before joining PMI, Pierre Le Manh recently led a project for the North American expansion of Galileo Global Education, a European leader in post-secondary higher education and education technology. Until 2021, he served as the Chief Executive Officer of North America and Global Deputy CEO of Ipsos, the global leader in market research and data analytics, where he played a key leadership role in the company’s global expansion for over 15 years, first as CEO for EMEA and then as global head of several professional practices before heading the North American business. Before Ipsos, he held several other CEO positions in technology-based services and publishing.

“I am very excited to leverage the broad and deep experience I have gained over my career to lead the PMI organization and, in particular, to create a stronger membership experience for project professionals seeking lifelong learning and development opportunities and for corporate partners investing in reskilling and upskilling their workforce,” Le Manh said.

About Project Management Institute (PMI)

Project Management Institute (PMI) is the leading professional development organization for project management and the authority for a growing global community of millions of professionals of the project economy who use project, program, and portfolio management skills and competencies.

Building on a proud legacy dating to 1969, PMI is a not-for-profit for-purpose organization working in nearly every country to advance careers, strengthen organizational success, and enable project professionals and changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.

PMI empowers people to make ideas a reality and helps professionals and changemakers create better outcomes for businesses, communities, and society worldwide. Through global advocacy, networking, collaboration, research, and education, PMI prepares organizations and individuals at every stage of their career journey to work smarter to drive success in a world of change.

Visit us at www.PMI.org , LinkedIn , https://www.facebook.com/PMInstitute , and on Twitter @PMInstitute .

Social Media:

https://www.facebook.com/PMInstitute

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye